Manage Account
Change Password
Sign Out
Entresto is indicated to reduce the risk of cardiovascular mortality and morbidity in adult patients with systolic heart failure (NYHA Class II-IV, LVEF ≤40%).
Entresto is administered in combination with other heart failure therapies (e.g. betablockers, diuretics and mineralocorticoid antagonists) as appropriate, in place of an ACE inhibitor or other ARB.
